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Abstract: Background
There is limited evidence on the influence of sex on decision to implant a cardiac
resynchronization therapy device with pacemaker (CRT-P) or defibrillator (CRT-D), and
the existence of sex-dependent differences in complications that may bias this
decision.
Methods
All patients undergoing de novo CRT implantation (2004-2014) in the United States
(US) National Inpatient Sample were included, stratified by device type (CRT-P and
CRT-D). Multivariable logistic regression models were conducted to assess the
association of female sex with receipt of CRT-D, and periprocedural complications.
Results
Out of 400,823 weighted CRT procedural records, the overall percentages of women
undergoing CRT-P and CRT-D implantations were 41.5% and 27.2%, respectively, and
these increased in comparison to males over the study period. Women were less likely
to receive CRT-D (OR 0.66 95% confidence interval (CI) 0.64-0.67) and this trend
remained stable throughout the study period (p=0.06). Furthermore, women were
associated with increased odds of procedure-related complications (bleeding, thoracic
and cardiac), compared to men, in the CRT-D group but not in the CRT-P group.
Factors such as atrial fibrillation, malignancies, renal failure, advanced age (>60 years)
and admission to non-urban/small hospitals favored the receipt of CRT-P over CRT-D
whereas history of ischemic heart disease, cardiac arrest or ventricular arrhythmias
favored the receipt of CRT-D over CRT-P.
Conclusion
Females were associated with persistently reduced odds of receipt of CRT-D
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compared to males over an eleven-year period. The present study identifies important
factors that predict the choice of CRT device patients receive in the US healthcare
system.




Dear Professor Stanley Nattel, MD, Editor in Chief, 
 
 We thank the Editorial Committee and the Reviewers for their valuable comments on 
the manuscript entitled ‘Trends of sex differences in outcomes of cardiac electronic device 
implantations in the United States’ and agree that these recommendations have further 
improved the readability of our study. We have responded to all the comments fully as outlined 
in the rebuttal and highlighted all changes in a marked copy of the manuscript.  
 We hope that we have addressed all reviewers’ comments sufficiently and hope that 
these changes will enable publication of our paper in the Canadian Journal of Cardiology.  
We list our reply to the reviewer’s comments in the file entitled ‘Response to 




Dr Mohamed Mohamed and Prof. Mamas Mamas 












Response to reviewers 
 
Reviewer #1: I thank my colleagues Mohamed et al for their thoughtful responses to my 
concerns and suggestions. I have no further major points to raise, but I do wish to make 
two last minor suggestions that I leave up to the authors to decide whether they feel are 
helpful or not. I do not feel replies to these final suggestions are necessary.  
 
Response: We thank you thank the reviewing for reassessing our updated manuscript, and we 
are delighted to know that their major concerns were addressed. We have responded to the 
reviewer’s final suggestions below.  
 
1. I agree with the authors that administrative data can be valuable for this type of 
research. The concern I raised in my point #10 was that the reference they use to a at 
least partially argues against the authors' point. Perhaps adding one or two more 
supportive references (e.g. those they cite in their RtR) might give more confidence in the 
importance of the results to readers less familiar with research using administrative 
data/.  
Response: We thank the reviewer for this suggestion and the references cited in our first 
rebuttal were now added to the relevant section in the limitations.  
 
2. I would consider changing the wording in the following sentence: "Female patients 
may have greater concerns about body image…". This could be viewed as a somewhat 
presumptuous statement that, I suggest, should be supported by empiric data if kept in 
the manuscript. The study they cite did NOT find differences in body image concerns 
between men and women, although that study does refer to one that suggested that 
YOUNGER women as a subgroup may have this concern more often. I think stating that 
sex differences in levels of anxiety and concerns regarding ICD implantation have been 
reported previously would probably be sufficient 
 
Response: We agree with the reviewer’s suggestion and we have now removed references to 
concerns about body image that may be viewed by some as a controversial statement.  
 
3. Kudos to the authors on an interesting manuscript 
Response: We thank the reviewer for their kind words.  
 
 
Reviewer #3: I have read the new version of the manuscript with interest. The authors 
have significantly improved the paper according to the reviewers comments. The message 
appears clearer and the removal of the reference to CRT response score make it less 
confusing. I think that this work represents valuable information that should be 
published 
 
I still have a few significant concerns: 
 
1-My most significant remaining concerns is the lack of clarity regarding the real sample 
size as mentioned in my previous comment, 
The authors state in the abstract: "Out of 400,832 de-novo CRT procedures analyzed" 
and in the results section : "A total of 400,823 de novo CRT implantation procedures 
were recorded". However, as clearly shown in the supplementary figure S1 this "400 823 
people population" is inferred from a sample of 84 184. Although the methods used to 
Detailed Response to Reviewers
make this inference are probably adequate as stated in the response, it is misleading for 
the reader to state that 400 823 patients were analyzed. The size of the sample analyzed 
should be made explicit in the main text in the methods and result section rather than 
only in the supplement.  
 
Response: We have made changes in the results and conclusion sections to further clarify that 
this is a weighted sample (quoted below and highlighted in the manuscript). We must 
emphasize that it is not our intention to mislead the readership or falsely inflate our sample 
size. We understand that even without application of discharge weight, a sample size of more 
than 80,000 is large enough to produce valid statistical inferences and would still be considered 
one of the largest analyses on this topic to date. However, we have an obligation to abide by 
HCUP sampling and analytical recommendations as stated in our Data User Agreement. These 
include the application of a sampling weight when running logistic regression models and 
reporting frequencies. Therefore, our analysis is only considered valid if reported using the 
weighted data.  
 
Under Abstract (results subheading):  
 
Out of 400,823 weighted CRT procedural records, the overall percentages of women 
undergoing CRT-P and CRT-D implantations were 41.5% and 27.2%, respectively, and these 
increased in comparison to males over the study period. 
 
Under Methods (Data source subheading):  
 
The NIS dataset constitutes a 20% stratified sample of US community hospitals and provides 
sampling weights to calculate national estimates that represent more than 95% of the US 
population. 
 
Under Results:  
 
A total of 84,148 individual records for de novo CRT implantation procedures were recorded 
between 2004 and 2014, which are representative of 400,823 estimated discharges after 




The present study is the largest to investigate sex differences in choice of CRT device type in 
more than 400,000 weighted hospitalization records (from 84,148 unweighted cases) for de 
novo CRT implantation and shows persistently lower odds of receipt of CRT-D in females 




2-In table 1, the number of patients when divided by sex are is not equal to the total 
numbers of patients divided by procedures (CRT-P-Male 39855 + CRT-P Female 28277 
+ CRT-D Male 282778 + CRT-D Female 105506 = 456 416 vs 60032 + 340791=400823). 
This should be verified and clarified 
 
Response: We thank the reviewer for highlighting this important point. The sample size is 
indeed 400,823 as mentioned in the manuscript. As the reviewer rightly pointed out, the 
individual numbers did not correspond to this total and this has now been corrected. An error 
in the SPSS filter function occurred when generating the individual group numbers after our 
analysis was complete, meaning that we the numbers reported were those prior to removing 
missing data. We have updated the CRT-P and CRT-D weighted values in Table 1. However, 
this does not affect our analysis and group numbers/percentages that were all correct and have 
been verified. We list below an output from SPSS shows the sample size and percentage for 
each study group and, as the reviewer will note, these numbers and group percentages match 
those in our paper (total sample size: 400,823, CRT-P vs. CRT-D: 15% vs. 85%, CRT-P-Male 
35107 + CRT-P Female 22925 + CRT-D Male 246015 + CRT-D Female 94776 = 400,823).  
 
Total sample size: 
 
Group absolute numbers and percentages:  
 
 
3-The advanced statistical methods are beyond my level of expertise and would benefit 
from a specific statistical review 
 
4-An important limitation that remains  is the lack of any information regarding the 
indication of the device including any data on LV function and presence of conditions 
requiring ventricular pacing. This is now better acknowledged in the discussion "we were 
unable to adjust for certain important factors such as exact LV function and conditions 
requiring a high proportion of right ventricular pacing". 
 
Response: We agree with the reviewer’s comments in that data on exact LV function and 
conditions requiring a high proportion of RV pacing remain as a limitation and, as the reviewer 
has kindly noted, we have acknowledged them both in the limitation section and discussion. 
Nevertheless, we feel that our study provides insights into differences in choice of CRT subtype 
in a large and unselected population, and we hope that this work inspires the conduct of further 
prospective studies to examine the observed disparities, adjusting for potential confounders 
that were not fully captured in our analysis.  
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Abstract 
Background: There is limited evidence on the influence of sex on decision to implant a 
cardiac resynchronization therapy device with pacemaker (CRT-P) or defibrillator (CRT-D), 
and the existence of sex-dependent differences in complications that may bias this decision.  
Methods: All patients undergoing de novo CRT implantation (2004-2014) in the United 
States (US) National Inpatient Sample were included, stratified by device type (CRT-P and 
CRT-D). Multivariable logistic regression models were conducted to assess the association of 
female sex with receipt of CRT-D, and periprocedural complications.  
Results: Out of 400,823 weighted CRT procedural records, the overall percentages of women 
undergoing CRT-P and CRT-D implantations were 41.5% and 27.8%, respectively, and these 
increased in comparison to males over the study period. Women were less likely to receive 
CRT-D (OR 0.66 95% confidence interval (CI) 0.64-0.67) and this trend remained stable 
throughout the study period (p=0.06). Furthermore, women were associated with increased 
odds of procedure-related complications (bleeding, thoracic and cardiac), compared to men, in 
the CRT-D group but not in the CRT-P group. Factors such as atrial fibrillation, malignancies, 
renal failure, advanced age (>60 years) and admission to non-urban/small hospitals favored the 
receipt of CRT-P over CRT-D whereas history of ischemic heart disease, cardiac arrest or 
ventricular arrhythmias favored the receipt of CRT-D over CRT-P.  
Conclusion: Females were associated with persistently reduced odds of receipt of CRT-D 
compared to males over an eleven-year period. The present study identifies important factors 
that predict the choice of CRT device patients receive in the US healthcare system.  
 







Cardiac resynchronization therapy (CRT) is a class I recommendation for the 
management of patients with symptomatic heart failure with reduced ejection fraction on 
guideline directed medical therapy and left bundle branch block (with a QRS duration >150 
milliseconds). 1-5 Decision making can be difficult in patients with Class 2a and 2b 
recommendations, such as those with atrial fibrillation, right bundle branch block or QRS 
duration <150 msec. In these situations, device type is often based on the implanters’ choice. 
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There is limited data on differences in the rate of utilization of both CRT device types 
between sexes, and whether sex is independently associated with the choice of device therapy. 
Findings from the recently published European Society of Cardiology (ESC) CRT Survey II 
concluded that females are more likely to receive a CRT-P (CRT with pacemaker) than a CRT-
D (CRT with defibrillator) device.7 In the absence of any randomized control trials, this survey 
was the first to examine predictors of receipt of CRT-P in a European cohort of more than 
10,000 patients undergoing CRT implantation between October 2015 and January 2017.  
However, only an estimated 11% of patients undergoing CRT were believed to have been 
enrolled in the survey making the findings less generalizable to the wider European population 
and other healthcare systems. Furthermore, it is unclear whether sex disparities in choice of 
CRT device type have changed from a national perspective over the years. The presence and 
trends of sex disparities regarding the type of CRT device as well as the difference in procedure 
related complications between sexes has not been evaluated in recent years. 
The present study examined the proportion of females undergoing implantation of 
CRT-P and CRT-D devices and evaluated the independent association between sex and choice 
of implanted CRT device type in a nationwide cohort of de novo CRT procedures performed 





The National Inpatient Sample (NIS) is the largest publicly available all-payer database 
of hospitalized patients in the US and is sponsored by the Agency for Healthcare Research and 
Quality as a part of the Healthcare Cost and Utilization Project (HCUP).8 NIS includes 
anonymized data on discharge diagnoses and procedures from more than 7 million 
hospitalizations annually. The NIS dataset constitutes a 20% stratified sample of US 
community hospitals and provides sampling weights to calculate national estimates that 
represent more than 95% of the US population. The estimates of hospital characteristics, 
numbers of discharges, length of stay, and in-hospital mortality from the HCUP NIS for 2007 
were highly comparable to three related data sources: the American Hospital Association 
(AHA) Annual Survey Database; the National Hospital Discharge Survey (NHDS) from the 
National Center for Health Statistics; and the MedPAR inpatient data from the Centers for 
Medicare and Medicaid Services (CMS). 9, 10 
 
Study Design and Population 
All adults (aged ≥18 years) undergoing de novo CRT implantation (CRT-P and CRT-
D) during hospitalization between 2004 and 2014 were included in this study, as identified 
using the International Classification of Diseases, ninth revision (ICD-9) codes given in Table 
S1 (Supplemental Material).  We excluded CRT upgrades and records with missing data on the 
following variables: age, elective admission, primary expected payer and median household 
income.  
Patient characteristics, comorbidities, and clinical outcomes were extracted using the 
ICD-9 procedure and diagnosis codes provided in Table S1 (Supplemental Material); 
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procedure-related bleeding, cardiac complications (composite of cardiac tamponade, 
hemopericardium, pericardial effusion and pericardiocentesis) and thoracic complications 
(composite of acute pneumothorax or hemothorax, with or without drainage, or thoracic 
vascular injury) were also extracted. Procedure-related bleeding was defined as any post-
procedural hemorrhage or anemia after hemorrhage according to ICD-9 diagnosis codes. 
(Table S1)  
Outcomes 
The primary outcome was comparison of receipt of CRT-D compared to CRT-P 
between sexes. The secondary outcomes were in-hospital adverse events, including major acute 
cardiovascular events (MACE), all-cause mortality and procedural-related complications 
(bleeding, thoracic and cardiac). In-hospital MACE was defined as a composite of all-cause 
mortality, cardiac complications, thoracic complications and device-related infection.  
Statistical Analysis 
For exploratory analysis, the cohort was stratified by device type (CRT-D, or CRT-P) 
and sex. Continuous variables are summarized using medians and interquartile range (IQR) 
and were compared using the Kruskal-Wallis test. Categorical variables are summarized as 
percentages and were analyzed using the chi-squared (X2) test.  
Several multivariable logistic regression models were constructed to examine the 
independent association between female sex and each of our outcomes of interest; first, receipt 
of CRT-D and second all of the procedure-related adverse events that we considered (stratified 
by device type). All multivariable models adjusted for differences in socioeconomic, clinical, 
and hospital-level covariates that may directly influence in-hospital outcomes (all variables 
listed in Appendix A in Supplemental Material). Trend analysis was performed using linear 
regression modelling with the inclusion of time (years) as a covariate for assessing sex 
differences in type of device use over time, and by assessing the interaction between sex and 
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time (years) in logistic regression analysis for clinical outcomes. All associations were 
summarized from the multivariable logistic regression models using odds ratios (ORs) and 
associated 95% confidence intervals (CIs). 
All statistical analyses were performed using SPSS version 24 (IBM Corp, Armonk, 
NY). Additionally, all analyses used the sampling weights provided by the AHRQ, which are 
required because the design of the study means that different observations may have different 
probabilities of selection. The sampling weights for each individual discharge were hence 
incorporated into the relevant SPSS commands for each analysis. 
Results 
A total of 400,823 de novo CRT implantation procedures were recorded between 2004 
and 2014, including 60,032 CRT-P procedures (15%) and 340,791 CRT-D procedures (85%). 
A flow diagram illustrating the inclusion and exclusion process in the present study is presented 
in Figure S1 (Supplemental Material).  Cases excluded due to missing variables represented 
3% (n=2601 unweighted records) of the CRT de novo implantation cohort. 
In the total cohort, 77% of females underwent CRT-D implantation compared to 88% 
of males, while the rest underwent CRT-P implantation. Within the CRT groups, females were 
more prevalent in the CRT-P group than the CRT-D group (41.5% vs. 27.8%). The percentage 
of females undergoing both CRT-P and CRT-D procedures amongst all CRT implantations has 
increased over the study period, but more so in the CRT-P group. Specifically, the percentage 
of females undergoing CRT-P was 34.9% in 2004, compared to 45.6% in 2014 (absolute 
difference of 10.7%), while the percentage of females undergoing CRT-D was 24.2% in 2004 
compared to 29.0% in 2014 (absolute difference of 4.8%). (Figure 1) 
Patients undergoing CRT-D were primarily younger with a greater burden of 
cardiovascular risk factors such a previous cardiac arrest, ventricular tachycardia (VT), 
ventricular fibrillation (VF), diabetes and a previous history of acute myocardial infarction 
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(AMI), percutaneous coronary intervention (PCI) and coronary artery bypass grafts (CABG). 
(Table 1) However, the CRT-D group had a lower prevalence of renal failure, anemias and 
coagulopathies. Several sex differences in patient characteristics were observed in both CRT 
groups. Females in both groups had significantly lower prevalence of VT, VF, renal failure and 
previous AMI, PCI, CABG and history of ischemic heart disease (IHD) but a much higher 
prevalence of non-ischemic cardiomyopathy.  
Predictors of receipt of CRT-D 
 Female sex was independently associated with lower odds of CRT-D compared to male 
sex in the total cohort (OR 0.66 95% CI 0.64 - 0.67), and this finding persisted throughout the 
study years (Pinteraction=0.06). (Table 2, Figure 2). Several other variables were predictive of 
receipt of CRT-D compared to CRT-P. (Table 2, Figures 3A and 3B) Older age was associated 
with a lower odds of CRT-D (Age (years) 61-70: OR 0.77 95% CI 0.74, 0.80; 71-80: OR 0.52 
95% CI 0.50- 0.54; >80: OR 0.22 95% CI 0.21 - 0.23], p<0.001 for all). (Figure 3A) The 
majority of primary expected payer categories were not associated with receipt of CRT-D over 
CRT-P; however, privately insured patients were less likely to receive a CRT-D device (OR 
0.84 [0.77, 0.91]) compared to those insured with Medicare. Furthermore, patients admitted to 
urban hospitals (teaching and non-teaching) and hospitals with a higher bed capacity (medium 
and large) were more likely to receive CRT-D (Table 2, Figure 3B).  
 Amongst the comorbidities, factors such as previous cardiovascular disease (acute 
myocardial infarction and coronary artery bypass graft), history of cardiac arrest and 
ventricular arrhythmias (ventricular tachycardia and fibrillation) were associated with 
increased odds of receipt of CRT-D whereas comorbidities such as atrial fibrillation, anemia 
(deficiency and chronic), renal failure and malignancy (solid tumors, metastatic cancers and 
lymphomas) were associated with reduced odds of receipt of CRT-D. (Table 2, Figure 3A).  
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In-hospital adverse outcomes 
Overall, the crude rates of mortality and adverse events were higher in the CRT-P group 
compared to CRT-D group (MACE: 4.8 vs. 7.0%; mortality: 0.8% vs. 1.4%; procedure-related 
bleeding: 1.9% vs. 3.5%; thoracic and complications: 2.6% vs. 4.2% and 0.4% vs. 0.5%, 
respectively. (Table 3) Within the CRT-P group, the rates of MACE, mortality, procedure-
related bleeding and device-related infection were lower in females compared to males, while 
the rate of cardiac complications was higher in females and there was no difference in thoracic 
complications between sexes. (Table 3, Figure S2) In contrast, in the CRT-D group, the 
majority of complications (MACE, procedure-related bleeding, thoracic and cardiac 
complications) were higher in females than in males, with the exception of mortality and 
device-related infections, which were lower in females. (Table 3, Figure S2) 
In multivariable analysis there was a sex-related difference in outcomes in the CRT-P 
and CRT-D groups. The odds of MACE were higher in females undergoing CRT-D (OR 1.10 
95% CI 1.06-1.14) but lower in females undergoing CRT-P implantation (OR 0.91 95% CI 
0.85-0.97). (Table 4) Further, the odds of procedure-related bleeding, thoracic and cardiac 
complications were significantly raised in females in the CRT-D group but there was no 
difference between sexes in the CRT-P group. However, females in both CRT groups were 
associated with reduced odds of mortality (CRT-P: OR 0.70 95% CI 0.59-0.82, CRT-D: OR 
0.73 95% CI 0.67-0.81). 
Discussion 
The current study is the largest to examine sex differences in the type of CRT device 
used in de novo implantations. We also present the largest analysis of predictors of receipt of 
CRT-D, compared to CRT-P, in a national cohort of CRT implantations in the US. Our key 
finding is that over a period of 11 years, among recipients of CRT, a larger proportion of 
females received CRT P as opposed to CRT D despite adjustment for baseline differences.  
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analysis demonstrates that females undergoing CRT-D implantation are at a higher risk of 
procedure-related complications (bleeding, thoracic and cardiac) compared to males, but no 
difference in these complications was observed between sexes in the CRT-P group.  We also 
report lower mortality in females undergoing implantation of both types of CRT devices 
compared to males. Finally, we observe institutional disparities in choice of CRT device, where 
patients admitted to urban and larger bed hospitals were more likely to receive CRT D, rather 
than CRT P.  
There are inconsistencies in the recommendations of international guidelines on choice 
of device type (CRT-D vs. CRT-P).11 The European Heart Rhythm Association recommends 
the consideration of factors such as life expectancy, severe renal failure and patient frailty 
status, however, in some circumstances, the decision on device type is often based on 
implanters’ choice rather than guideline recommendations.1, 11 Despite sex not being a factor 
in the choice of device type, there have been several reports on the lower rates of CRT-D 
implantation in females compared to males.7, 12 However, studies to date were insufficiently 
powered to inform cardiologists of the trends of sex differences in the choice of device or 
subsequent outcomes in patients undergoing CRT-D implantation. Findings from the ESC 
Survey II showed that females were less likely to receive a CRT-D device in a survey of more 
than 10000 patients undergoing CRT implantation in Europe,7 but these findings were limited 
by a small cohort that was collected over 15 months and estimated to represent only 11% of all 
procedures undertaken throughout this period. A study of more than 300,000 patients 
undergoing CRT-D implantation between 2006 and 2012 showed that women were less likely 
to receive CRT-D.13  However, their trend analysis only comprised of crude rates without 
adjustment for baseline differences in characteristics between sexes in both device groups and, 
as such, appeared significant. Our study examines trends over a longer period (2004-2014) and 
demonstrates sex disparities in choice of CRT device, with females persistently less likely to 
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receive a CRT-D device compared to CRT-P over an eleven-year period, despite adjustment 
for all feasible baseline differences between the study groups, and shows that the trend was 
insignificant. However, we were unable to adjust for certain important factors such as exact 
LV function and conditions requiring a high proportion of right ventricular pacing. Possible 
explanations for the persistent sex differences in choice of CRT type could be lower referral of 
females for CRT, females’ reduced access of to  healthcare compared to men, and  physicians’ 
belief that females are better responders to CRT with improved LV reverse remodeling, as 
evidenced by normalization of QRS duration, and reduced longer term mortality compared to 
males and, therefore, less likely to experience ventricular arrhythmias requiring defibrillation, 
as well as patient preferences.14-16 However, there is growing evidence to suggest that QRS 
duration alone is less reliable for the assessment of dyssynchrony, especially between sexes, 
since females have smaller left ventricles and an apparently normal QRS duration may still be 
dyssynchronous in relation to the right ventricle when not adjusted for LV mass.14 An 
important consideration influencing the choice of device is patient preference. Female patients 
may have greater concerns about body image, especially with CRT-D devices that have bulkier 
generators, and ICD shocks. A study on sex differences in anxiety and concerns in 535 patients 
undergoing ICD implantation, female sex was associated with increased odds of anxiety (OR 
2.60 95% CI 1.46–4.64) and concerns about ICD shocks (OR 1.81 95% CI 1.09–3.00) 
compared to male sex. 17 These factors may affect patient preferences and should be addressed 
when counselling them prior to CRT implantation.  
Our study is the largest to examine and demonstrate disparities in outcomes according 
to sex between CRT-D and CRT-P groups, except in mortality, which was reduced in females 
regardless of CRT subtype. We show that there are no differences in CRT-P procedure-related 
complications between sexes whereas females were at a higher risk of all CRT-D procedure-
related complications (bleeding, cardiac and thoracic) compared to males. The increased risk 
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of complications in females undergoing CRT-D insertion is possibly attributed to the use of 
bulky defibrillator leads relative to females, who have thinner ventricles, smaller cardiac 
chamber sizes, and smaller vessel size and diameter, which may, in part, explain operators’ 
reluctance to choose CRT-D devices over CRT-P in females; however the reasons are 
multifactorial and include factors such as patient preferences and device indication.18-2223 
While the ESC Survey II study did not demonstrate a difference in complications between 
CRT-P and CRT-D devices,7 their major complications did not include mechanical factors 
such as thoracic (pneumothorax or hemothorax), cardiac (pericardial effusion or tamponade) 
and vascular complications (thoracic vessels and coronary sinus vascular injuries) and were 
only restricted to stroke, myocardial infarction, infection, arrhythmias and worsening heart and 
renal failure. In contrast, a study by Barra et al. of 3008 European patients undergoing CRT 
implantation between 2006 and 2013 showed no significant differences in the odds of acute 
complications in patients undergoing CRT-D devices (OR=1.16, 95% CI 0.71-1.89, p=0.56).24 
The increased risk of procedure-related complications in females undergoing CRT-D 
implantation observed in some studies may explain operators’ reluctance to opt for CRT-D 
devices in females. These findings highlight the need for devices that have been designed for 
females (accounting for their biology, size) as much as males, and the need to increase the 
enrollment of females in clinical trials that establish the efficacy and safety of devices. 
Furthermore, risk reduction strategies such as ultrasound and echocardiography guidance for 
venous access and septal RV lead placements, respectively, could help reduce their risk of 
complications in females.  
The present study reports several important predictors of receipt of CRT-D over CRT-
P in a contemporary cohort of US hospitalizations. A recent study has examined factors that 
affect the choice of CRT device type in a European population.7 However, there are several 
differences between healthcare and insurance systems between both continents and the findings 
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from the ESC Survey II may not inform US operators of contemporary practice from a national 
perspective. Several predictors of receipt of CRT-D were similar between our study and the 
ESC Survey II such as sex, admission to a university hospital (approximately equivalent to an 
urban teaching hospital) and also factors in favor of receipt of CRT-P device such as atrial 
fibrillation.7 While younger patients (≤75 years) were more likely to receive a CRT-P device 
in the ESC survey, we show that the odds of receipt of CRT-D start from an age of 60 years 
with an inverse relationship between age and odds of receipt of CRT-D in older age groups 




There are several limitations to our study. First, the administrative nature of the NIS 
database, as with any such database has limitations around the accuracy of coding with no 
external validation. However, the use of administrative data has been previously validated for 
the purpose of cardiovascular research 25, and for capturing CIED-related complications.26 
Furthermore, the NIS database has a comparable capture of patient demographics and superior 
geographic capture of hospitalizations in more than 25 diagnosis groups in comparison to large 
multistate electronic health record databases.27 Secondly, since the NIS dataset does not 
provide information on pharmacotherapy, indications for CRT implantation, site of LV 
placement, ejection fraction, QRS duration, etiology of heart failure and operator experience, 
we were unable to adjust for the differences in these covariates between the study groups. We 
were unable to account for patient preference or consent as factors in device selection. 
Furthermore, due to the observational nature of these data, the results should not be interpreted 
as causal, but rather relate to associations that require further research. Third, our cohort 
includes a mixture of daycase and inpatient procedures and, therefore, may not be reflective of 
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simple outpatient procedures. Finally, the NIS dataset only reports in-hospital outcomes and, 
therefore, the present findings are not be applicable to longer term outcomes.  
Conclusion 
 The present study is the largest to investigate sex differences in choice of CRT device 
type in 400,000 hospitalizations for de novo CRT implantation and shows persistently lower 
odds of receipt of CRT-D in females compared to males over an eleven year period. Females 
undergoing CRT-D implantation are at a higher risk of procedure-related complications 
compared to males, but no difference was found in procedure-related complications between 
sexes in those undergoing CRT-P implantations. The present study shows significant 
disparities in choice of CRT type between geographical regions and institutional levels and 
identifies patient factors that favor receipt of either type of device. These findings are essential 
to inform operators of the trends of current practice from a national perspective and drive the 
need for further research in to sex differences in complications in patients undergoing CRT-D 
implantation which may be deterring operators from offering these devices to females 
compared to males.  
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Figure 1. Proportions of A) CRT-P and B) CRT-D procedures over the study period* 
 
Legend: *p<0.001 for trend; CRT-P & CRT-D: cardiac resynchronization therapy - 
pacemaker or - defibrillator, respectively 
 
Figure 2. Odds ratios (OR) of receipt of CRT-D as opposed to CRT-P in females* 
 
Legend: *reference is male sex; CI: confidence interval; CRT-P & CRT-D: cardiac 
resynchronization therapy - pacemaker or - defibrillator, respectively; p>0.05 (non-significant 
for trend) 
 
Figure 3. Patient-related (A) and non-patient-related (B) predictors of receipt of CRT-D 
as opposed to CRT-P in females* 
 
Legend: *reference is male sex; § non-significant; † p<0.05; ‡ p<0.001; CI: confidence 
interval; OR: odds ratio; CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker or 
- defibrillator, respectively.  
Table 1. Patient characteristics of study groups  











p-value CRT-P CRT-D 
p-
value 
Number of weighted 
discharges 
35107 24925  246015 94776  60032 340791  
Sociodemographic          
Age (years), median (IQR) 77(68,83) 78(69,84) <0.001 71(62,78) 71(62,78) 0.08 77 (69,83) 71 (62,78) <0.001 
Ethnicity, %   <0.001   <0.001   <0.001 
White 84.0 81.3  79.9 72.0  83.0 78.0  
Black 6.5 9.1  9.4 15.9  7.5 11.2  
Hispanic 5.3 5.4  6.2 7.5  5.3 6.4  
Asian/Pacific Islander 1.2 1.4  1.3 1.3  1.3 1.3  
Native American 0.7 0.8  0.5 0.6  0.7 0.5  
Other 2.4 2.1  2.6 2.7  2.2 2.6  
Elective Admission, % 44.5 42.9 <0.001 50.3 50.2 0.673 43.9 50.3 <0.001 
Weekend admission, % 11.1 10.7 <0.001 9.0 8.9 0.429 10.9 9.0 <0.001 
Primary expected payer, %   <0.001   <0.001   <0.001 
Medicare 78.3 82.3  71.7 71.3  80.1 71.7  
Medicaid 3.0 3.2  4.5 6.5  3.0 5.0  
Private Insurance 15.9 12.4  20.3 19.2  14.5 20.0  
Self-pay 1.1 1.0  1.6 1.6  1.0 1.5  
No charge 0.0 0.1  0.2 0.2  0.1 0.2  
Other 1.7 0.9  1.7 1.2  1.3 1.6  
Median Household Income 
(Percentile), % 
  <0.001   <0.001   <0.001 
0-25th 23.3 27.2  25.5 29.5  24.9 26.5  
26-50th 26.2 27.2  26.3 26.9  26.6 26.5  
51-75th 26.7 24.8  25.3 23.5  25.9 24.8  
76-100th 23.9 20.9  22.9 20.1  22.7 22.2  
Hospital bed size, %   <0.001   <0.001   <0.001 
Table 1











p-value CRT-P CRT-D 
p-
value 
Small 9.4 10.8  8.5 8.1  10.0 8.4  
Medium 19.6 19.1  18.4 19.7  19.4 18.7  
Large 71.0 70.1  73.1 72.2  70.6 72.9  
Hospital Region, %   <0.001   <0.001   <0.001 
Northeast 15.8 14.3  20.7 19.6  15.0 20.4  
Midwest 28.6 29.2  25.1 25.9  29.1 25.5  
South 39.0 40.3  37.4 38.9  39.5 37.7  
West 16.6 16.2  16.9 15.6  16.3 16.3  
Location/ Teaching status, 
% 
  <0.001   <0.001   <0.001 
Rural 5.4 6.5  3.3 3.2  5.8 3.2  
Urban non-teaching 32.7 33.1  35.4 34.1  32.8 35.0  
Urban- teaching 61.9 60.4  61.4 62.7  61.4 61.8  
Length of stay (days), %   0.232   0.162   0.04 
0-1 42.4 39.1  40.0 39.4  40.8 39.2  
2 10.7 10.8  9.8 10.1  9.9 10.2  
Comorbidities, %          
All-cause infection* 2.5 1.9 <0.001 1.8 1.6 <0.001 2.2 1.7 <0.001 
Cardiac Arrest 1.6 1.4 0.086 2.1 2.5 <0.001 1.5 2.2 <0.001 
Shock 1.7 1.5 0.032 1.9 1.6 <0.001 1.6 1.8 <0.001 
LBBB 73.3 70.4 <0.001 76.0 74.1 <0.001 74.6 72.8 <0.001 
Atrial Fibrillation 52.0 58.3 <0.001 36.7 29.2 <0.001 54.7 34.8 <0.001 
Ventricular Tachycardia 10.2 6.0 <0.001 29.3 22.1 <0.001 8.4 27.4 <0.001 
Ventricular Fibrillation 0.9 0.8 0.712 3.9 4.1 0.017 0.8 3.9 <0.001 
Anemias 12.8 15.6 <0.001 9.2 11.7 <0.001 9.6 12.5 <0.001 
Coagulation disorders 6.2 4.1 <0.001 4.1 3.0 <0.001 4.4 3.3 <0.001 
Diabetes 29.0 27.1 0.015 33.4 34.1 0.063 32.9 32.7 0.576 
Hypertension 57.1 61.4 <0.001 56.3 56.4 0.696 58.9 56.4 <0.001 











p-value CRT-P CRT-D 
p-
value 
Renal failure (chronic) 22.0 18.5 <0.001 20.2 15.9 <0.001 20.6 19.1 <0.001 
Peripheral vascular disease 9.5 6.7 <0.001 9.7 6.7 <0.001 8.3 8.9 <0.001 
Valvular heart disease 1.1 1.4 <0.001 0.6 0.8 <0.001 1.2 0.6 <0.001 
Previous AMI 13.2 9.0 <0.001 23.9 15.5 <0.001 11.5 21.7 <0.001 
History of IHD 58.9 41.4 <0.001 72.1 52.2 <0.001 51.6 66.7 <0.001 
Previous PCI 10.2 8.1 <0.001 13.0 9.5 <0.001 9.4 12.1 <0.001 
Previous CABG 19.7 8.9 <0.001 26.1 12.6 <0.001 15.2 22.4 <0.001 
Previous CVA 4.4 5.3 <0.001 3.6 3.5 0.161 4.8 3.6 <0.001 
Dyslipidemia 39.6 38.4 0.001 42.7 38.5 <0.001 39.2 41.6 <0.001 
Smoking 5.2 3.7 <0.001 7.7 6.1 <0.001 4.6 7.3 <0.001 
Chronic pulmonary disease/ 
pulmonary circulation 
disorders 
22.1 21.7 0.569 21.2 22.6 <0.001 21.3 22.4 0.001 
Hypothyroidism 8.7 21.0 <0.001 7.1 15.2 <0.001 13.9 9.3 <0.001 
RA/collagen vascular 
diseases 
1.6 3.5 <0.001 1.1 2.9 <0.001 2.4 1.6 
<0.001 
Liver disease 1.1 0.8 <0.001 1.1 0.8 <0.001 1.0 1.0 0.679 
Fluid and electrolyte 
disturbances 
16.2 19.1 <0.001 12.8 14.7 <0.001 17.5 13.3 
<0.001 
Malignancies** 3.0 2.0 <0.001 1.5 1.3 0.066 1.7 1.3 0.017 
Depression and/or psychosis 4.8 8.9 <0.001 4.1 7.5 <0.001 4.2 7.8 <0.001 
Paralysis and other 
neurological disorders 
4.9 4.7 0.699 3.1 3.4 0.026 3.3 3.7 0.006 
Obesity 7.2 9.0 <0.001 8.4 10.4 <0.001 8.1 8.9 <0.001 
Weight loss 2.5 2.5 0.831 1.3 1.4 0.020 2.5 1.3 <0.001 
Dementia 1.0 1.1 0.233 0.3 0.3 0.320 1.1 0.3 <0.001 
*All-cause infection: Composite of septicemia, viremia and bacteremia; **including hematological malignancies (e.g. lymphoma and leukemia); CRT-P & CRT-D: cardiac 
resynchronization therapy - pacemaker or - defibrillator, respectively; IQR: interquartile range; AMI: acute myocardial infarction; IHD: ischemic heart disease; CABG: 
coronary artery bypass graft; PCI: percutaneous coronary intervention; CAD: coronary artery disease; LBBB: left bundle branch block 
Table 2. Multivariable analysis of predictors of receipt of CRT-D Device* 
Predictor OR [95% CI] 
Female sex 0.66 [0.64, 0.67] 
Age (Years)  
≤60 (reference)  
61-70 0.77 [0.74, 0.80] 
71-80 0.52 [0.50, 0.54] 
>80 0.22 [0.21, 0.23] 
Primary payer  
Medicare (reference)   
Medicaid 1.03 [0.98, 1.09] 
Private Insurance 0.94 [0.91, 0.97] 
Self-pay 0.92 [0.84, 1.00] 
No charge 1.33 [0.99, 1.78] 
Shock 1.01 [0.93, 1.08] 
Cardiac Arrest 1.09 [1.01, 1.18] 
Ventricular Tachycardia 4.09 [3.97, 4.22] 
Ventricular Fibrillation 4.37 [3.99, 4.79] 
Dyslipidemia 1.04 [1.02, 1.06] 
Atrial Fibrillation 0.53 [0.52, 0.54] 
Thrombocytopenia 0.82 [0.74, 0.90] 
Previous AMI 1.56 [1.52, 1.61] 
Previous PCI 0.95 [0.92, 0.98] 
Previous CABG 1.21 [1.17, 1.24] 
Previous CVA 0.89 [0.85, 0.93] 
Family history of CAD 1.01 [0.95, 1.07] 
Alcohol abuse 0.97 [0.89, 1.05] 
Deficiency anemias 0.84 [0.82, 0.87] 
Chronic blood loss anemia 0.85 [0.76, 0.95] 
RA/collagen vascular 
diseases 
0.81 [0.76, 0.86] 
Chronic pulmonary disease 0.94 [0.91, 0.96] 
Coagulopathy 1.00 [0.92, 1.09] 
Depression 0.87 [0.83, 0.91] 
Diabetes 1.11 [1.09, 1.14] 
Drug abuse 1.06 [0.93, 1.20] 
Hypertension 0.94 [0.92, 0.96] 
Hypothyroidism 0.89 [0.86, 0.91] 
Liver disease 0.88 [0.80, 0.97] 
Lymphomas 0.65 [0.59, 0.72] 
Fluid and electrolyte disturbances 0.83 [0.81, 0.85] 
Metastatic cancer 0.52 [0.44, 0.62] 
Other neurological disorders 0.80 [0.76, 0.84] 
Paralysis 0.89 [0.81, 0.99] 
Peripheral vascular disease 0.99 [0.96, 1.03] 
Pulmonary circulation disorder 0.54 [0.47, 0.62] 
Table 2
Renal failure (chronic) 0.89 [0.85, 0.96] 
Solid tumor without metastases 0.76 [0.70, 0.83] 
Valvular heart disease 0.81 [0.74, 0.90] 
Weight loss 0.64 [0.60, 0.69] 
Dementia 0.53 [0.47, 0.60] 
Hospital bed size  
Small (reference)  
Medium 1.19 [1.15, 1.23] 
Large 1.26 [1.23, 1.31] 
Hospital Region  
Northeast (reference)  
Midwest 0.65 [0.63, 0.67] 
South 0.66 [0.64, 0.68] 
West 0.74 [0.72, 0.77] 
Location/ Teaching status  
Rural (reference)  
Urban non-teaching 1.96 [1.87, 2.05] 
Urban- teaching 1.72 [1.65, 1.80] 
*Indicator is receipt of CRT-P adjusting for the above variables and calendar year.  
As an example, odds ratio of 0.56 favors receipt of CRT-P over CRT-D; CI: Confidence Interval; OR: Odds 
ratio; CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker or - defibrillator, respectively; IQR: 
interquartile range; AMI: acute myocardial infarction; CABG: coronary artery bypass graft; PCI: percutaneous 
coronary intervention; CAD: coronary artery disease.  
 
 
Table 3. In-hospital clinical outcomes according to device type 
*MACE: Composite of mortality, thoracic complications, cardiac complications, and device-related infection; CRT-































MACE, %* 7.3 6.6 0.002 4.7 5.2 <0.001 7.0 4.8 <0.001 
All-cause 
mortality, % 
1.6 1.1 <0.001 0.8 0.6 <0.001 1.4 0.8 <0.001 
Procedure-related 
bleeding, % 
3.6 3.3 <0.001 1.8 2.1 <0.001 3.5 1.9 <0.001 
Thoracic 
complications, % 
4.1 4.4 0.065 2.3 3.3 <0.001 4.2 2.6 <0.001 
Cardiac 
complications, % 
0.4 0.5 0.025 0.3 0.6 <0.001 0.5 0.4 <0.001 
Device-related 
infection, %* 
1.8 1.1 <0.001 1.6 0.9 <0.001 1.5 1.4 0.021 
Table 3
Table 4. Odds ratios (OR) of in-hospital outcomes in females (vs. males) 
 CRT-P CRT-D 
 OR [95% CI] OR [95% CI] 
MACE* 0.91 [0.85,0.97] 1.10 [1.06,1.14] 
All-cause mortality 0.70 [0.59,0.82] 0.73 [0.67,0.81] 
Procedure-related bleeding 1.00 [0.91,1.10] 1.23 [1.17,1.31] 
Thoracic complications 1.04 [0.96,1.13] 1.39 [1.33,1.45] 
Cardiac complications 1.10 [0.87,1.39] 1.69 [1.50,1.90] 
*MACE: Composite of mortality, thoracic complications, cardiac complications, and 
device-related infection; CI: confidence interval; CRT-P & CRT-D: cardiac resynchronization 
therapy - pacemaker or - defibrillator, respectively 
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